AffiliationDepartment of Endocrinology, Christie Hospital NHS Trust, Manchester, UK.
MetadataShow full item record
AbstractData collected from 102 neurofibromatosis (NF) children with growth hormone (GH) deficiency (GHD) who were receiving GH replacement therapy were reviewed to assess the efficacy and safety of GH therapy in this condition. GH was administered at a mean dose of 0. 18 mg/kg/week. During the 1st year the median height velocity increased significantly from 4.2 cm/year before treatment to 7.1 cm/year, and the median height standard deviation score increased from -2.4 to -1.9. The response to therapy, however, was not as good as that observed in patients with idiopathic GHD. GH therapy did not influence the progression of any of the features of NF, including intracranial tumours, and was not associated with an excess of other adverse events. We conclude that GH treatment of NF patients with GHD is beneficial in terms of improved growth rate and is well tolerated.
CitationGrowth hormone and neurofibromatosis. 2000, 53 Suppl 1:70-6 Horm. Res.
- Response to growth hormone treatment in isolated growth hormone deficiency versus multiple pituitary hormone deficiency.
- Authors: Darendeliler F, Lindberg A, Wilton P
- Issue date: 2011
- Adult height after growth hormone treatment in Japanese children with idiopathic growth hormone deficiency: analysis from the KIGS Japan database.
- Authors: Fujieda K, Tanaka T, Takano K, Chihara K, Seino Y, Irie M, KIGS Japan Scientific Committee.
- Issue date: 2011
- Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study.
- Authors: Cappa M, Iughetti L, Loche S, Maghnie M, Vottero A, GeNeSIS National Board on behalf of the GeNeSIS Italian Investigators.
- Issue date: 2016 Jun
- Growth hormone regimens in Australia: analysis of the first 3 years of treatment for idiopathic growth hormone deficiency and idiopathic short stature.
- Authors: Hughes IP, Harris M, Choong CS, Ambler G, Cutfield W, Hofman P, Cowell CT, Werther G, Cotterill A, Davies PS, Australasian Paediatric Endocrine Group (APEG).
- Issue date: 2012 Jul
- Growth hormone replacement and the risk of malignancy in children with neurofibromatosis.
- Authors: Howell SJ, Wilton P, Lindberg A, Shalet SM
- Issue date: 1998 Aug